Compare Realty Income Corp (O) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Realty Income Corp vs Tango Therapeutics Inc. — how do they compare? Realty Income Corp trades at $55.64 (market cap $52.03B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Realty Income Corp is far larger — about 13.9× Tango Therapeutics Inc.'s market cap, and Realty Income Corp pays a 5.92% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 128 Days and Tango Therapeutics Inc. for 0 Days on average.
| O | TNGX | |
|---|---|---|
Market Cap | $52.03B | $3.75B |
Volume | 16,838,213 | 9,619,106 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $32.90 |
52-Week Low | $53.35 | $7.50 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $82.66B | $2.77B |
Dividend Yield | 5.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $54.99, up 0.53% on the day, but remains in a bearish technical trend amid recent earnings misses. The stock's valuation appears elevated with a P/E of 40.14 and P/S of 8.53, though profitability is strong with a 92.56% gross margin. Recent news highlights the stock's decline as Treasury yields rise, pressuring REIT valuations, while the company maintains a robust dividend history with consistent monthly payouts.
Outlook: Moderate upside to the $64.16 consensus price target exists, supported by solid fundamentals and high analyst buy ratings, but risks include interest rate sensitivity, debt growth, and competitive pressures. The stock offers income appeal but faces near-term headwinds from macroeconomic conditions.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
